8-K: American Shared Hospital Services Reports Strong Revenue Growth in Q3 2024 Despite Profitability Challenges

American Shared Hospital Services saw a 36.3% increase in revenue in the third quarter of 2024, driven by recent acquisitions, but experienced a decrease in profitability due to increased operating costs and lower Gamma Knife treatment volumes.

Summary

• American Shared Hospital Services (ASHS) reported a 36.3% increase in total revenue for the third quarter of 2024, reaching $6.999 million, compared to $5.134 million in the same period of 2023.
• The revenue growth was primarily driven by the acquisition of 60% equity interest in two Rhode Island entities and the opening of a new facility in Puebla, Mexico.
• Direct patient services revenue increased significantly by 273.2% to $3.687 million, largely due to the Rhode Island and Puebla facilities.
• However, medical equipment leasing revenue decreased by 16.1% to $3.312 million due to lower Gamma Knife treatment volumes.
• The company experienced a net loss of $207,000, or ($0.03) per diluted share, compared to a net income of $118,000, or $0.02 per diluted share, in the third quarter of 2023.
• Adjusted EBITDA was $1.366 million for the third quarter of 2024, down from $1.669 million in the same period last year.
• Gross margin decreased to 19.6% of revenue, compared to 40.9% in the prior year, and operating income decreased by $979,000.
• Proton beam radiation therapy revenue increased by 4.4%, with treatments increasing by 5.4%.
• Gamma Knife revenue decreased by 32.9% due to contract expirations, equipment downtime, and staffing shortages.
• For the first nine months of 2024, revenue increased by 23.3% to $19.271 million, and net income was $3.514 million, or $0.54 per diluted share, primarily due to a bargain purchase gain from the RI Acquisition.

Sentiment

Score: 5

Explanation: The document presents mixed results with strong revenue growth offset by decreased profitability and operational challenges. While the company is optimistic about future growth, the current financial performance raises concerns.

Positives

• The company experienced a significant 36.3% increase in total revenue in the third quarter of 2024.
• Direct patient services revenue saw a substantial 273.2% increase, driven by the Rhode Island and Puebla facilities.
• Proton beam radiation therapy revenue increased by 4.4% with a 5.4% increase in treatments.
• The company's cash position increased to $14.077 million as of September 30, 2024, compared to $13.808 million at the end of 2023.
• Shareholders' equity increased to $26.423 million, or $4.14 per outstanding share, as of September 30, 2024, compared to $22.624 million, or $3.59 per outstanding share, at the end of 2023.
• For the first nine months of 2024, net income was $3.514 million, or $0.54 per diluted share, primarily due to a bargain purchase gain from the RI Acquisition.

Negatives

• The company reported a net loss of $207,000, or ($0.03) per diluted share, in the third quarter of 2024, compared to a net income of $118,000 in the same period of 2023.
• Gross margin decreased significantly to 19.6% of revenue, compared to 40.9% in the prior year.
• Operating income decreased by $979,000 compared to the third quarter of 2023.
• Medical equipment leasing revenue decreased by 16.1% due to lower Gamma Knife treatment volumes.
• Gamma Knife revenue decreased by 32.9% due to contract expirations, equipment downtime, and staffing shortages.
• Adjusted EBITDA decreased to $1.366 million in Q3 2024 from $1.669 million in Q3 2023.
• Operating loss for the third quarter was $889,000 compared to operating income of $90,000 in the prior year quarter.

Risks

• The company faces risks related to economic and market conditions.
• There is a risk of variability in financial results between quarters.
• The Gamma Knife and proton therapy businesses face inherent risks.
• Changes to CMS reimbursement rates or methodology could impact the company.
• The timing, financing, and operations of the company's Gamma Knife, proton therapy, and MR/LINAC businesses pose risks.
• Expanding into new markets carries risks.
• The integration and operation of acquired businesses could adversely affect financial results.
• Current and future acquisitions may negatively affect the company's financial position.

Future Outlook

The company anticipates seeing the benefits of implemented operating efficiencies in future quarters and expects continued growth supported by a strong balance sheet and consistent cash flow. The company is also focused on strategic growth initiatives to drive patient volumes and improve margins.

Management Comments

• Ray Stachowiak, CEO and Executive Chairman, stated that the third quarter marks another quarter of strong revenue growth and that the company is pleased with its solid revenue growth as it continues to execute on its long-term growth strategy.
• Ray Stachowiak also noted that the quarter's margins and profitability were affected by lower Gamma Knife treatment volumes, additional equipment service and preventative maintenance costs, and other operating efficiencies being implemented in Rhode Island, but anticipates seeing the benefits in future quarters.
• Gary Delanois, Executive Vice President and Chief Operating Officer, mentioned that the company's growth strategy is taking hold with its expanded product portfolio and increased capacity for creative financial solutions.
• Gary Delanois also stated that the company is implementing strategic growth initiatives to drive growth in patient volumes which will improve margins and overall profitability.

Industry Context

This announcement reflects a trend in the healthcare industry where companies are expanding their services through acquisitions and new facilities to increase revenue. However, it also highlights the challenges of integrating new operations and maintaining profitability, especially in the face of fluctuating treatment volumes and increased operating costs. The company's focus on advanced radiation therapy aligns with the growing demand for innovative cancer treatment solutions.

Comparison to Industry Standards

• While ASHS experienced a 36.3% revenue increase, this growth is not uniform across all segments, with leasing revenue declining by 16.1%. This contrasts with some medical equipment leasing companies that have seen more stable or growing revenues in the same period.
• The decrease in gross margin to 19.6% is significantly below the industry average for healthcare service providers, which often see margins in the 30-50% range. For example, companies like Varian Medical Systems, which also provides radiation therapy equipment, typically maintain higher gross margins.
• The net loss of $207,000 is a concern, as many healthcare companies of similar size are reporting profits. For example, Accuray, a competitor in the radiation therapy space, has shown varying profitability but has not consistently reported losses.
• The adjusted EBITDA of $1.366 million is lower than the previous year, indicating a potential challenge in maintaining profitability despite revenue growth. Companies like Elekta, another competitor in the radiation therapy market, often report higher EBITDA margins.
• The 4.4% increase in proton therapy revenue is modest compared to the growth rates seen in some other areas of the healthcare sector, where some companies are experiencing double-digit growth in specific treatment modalities.
• The 32.9% decrease in Gamma Knife revenue is a significant concern, as it indicates a potential weakness in this segment. Other companies in the radiosurgery market have not reported such steep declines, suggesting that ASHS may be facing unique challenges in this area.

Stakeholder Impact

• Shareholders may be concerned about the net loss and decreased profitability in the third quarter.
• Employees may be affected by the implementation of new operating efficiencies.
• Customers may benefit from the expanded services and facilities.
• Suppliers may see increased business due to the company's growth.
• Creditors may be monitoring the company's financial performance.

Next Steps

• The company plans to implement operating efficiencies in Rhode Island.
• The company will focus on strategic growth initiatives to drive patient volumes.
• The company will continue to pursue new business opportunities.
• The company will monitor and address the issues impacting Gamma Knife treatment volumes.

Key Dates

Keywords

radiosurgery, radiation therapy, cancer treatment, Gamma Knife, proton therapy, medical equipment leasing, healthcare, EBITDA, revenue, acquisition